SITC 2024 | T cell responses in responders vs. non-responders to oncolytic virotherapy in bladder cancer
Roger Li, MD, H Lee Moffitt Cancer Center, Tampa, FL, comments on the differences in T cell responses between responders and non-responders to treatment observed in the Phase Ib trial (NCT04610671) of the oncolytic virotherapy, cretostimogene grenadenorepvec, combined with nivolumab in muscle-invasive bladder cancer. Responders showed a tumor-specific T cell response with specific markers and a systemic anti-tumor response generated during treatment, whereas non-responders did not exhibit this response. This suggests that a cancer-specific response is induced systemically in certain patients, but not in others. This interview took place at the SITC 2024 congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
